Last reviewed · How we verify
Fotemustine and Ipilimumab
Fotemustine is a nitrosourea chemotherapy agent combined with ipilimumab, a CTLA-4 inhibitor that enhances anti-tumor immunity by blocking immune checkpoint inhibition.
Fotemustine is a nitrosourea chemotherapy agent combined with ipilimumab, a CTLA-4 inhibitor that enhances anti-tumor immunity by blocking immune checkpoint inhibition. Used for Metastatic melanoma.
At a glance
| Generic name | Fotemustine and Ipilimumab |
|---|---|
| Also known as | Fotemustine (Muphoran);, Ipilimumab (YERVOY) |
| Sponsor | Italian Network for Tumor Biotherapy Foundation |
| Drug class | Chemotherapy + immune checkpoint inhibitor combination |
| Target | DNA alkylation (fotemustine); CTLA-4 (ipilimumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Fotemustine is an alkylating agent that damages tumor cell DNA, while ipilimumab blocks CTLA-4 on T cells, removing inhibitory signals and enhancing T-cell activation and proliferation against cancer cells. The combination aims to leverage chemotherapy-induced tumor cell death with enhanced immune checkpoint blockade to improve anti-tumor immune responses.
Approved indications
- Metastatic melanoma
Common side effects
- Immune-related colitis
- Immune-related hepatitis
- Immune-related pneumonitis
- Myelosuppression
- Nausea and vomiting
- Fatigue
Key clinical trials
- A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis (PHASE3)
- A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: